Business Context and Reporting Period
This Form 6-K filing by Farmmi, Inc. covers the month of June 2025. The registrant is a foreign private issuer based in Lishui, Zhejiang Province, China. The report details specific corporate restructuring activities involving the divestiture and dissolution of wholly owned subsidiaries.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period. The only financial figures disclosed relate to specific asset sales:
- Guoning Zhonghao (Ningbo) Trade Co., Ltd.: Sold for RMB 10,000 (approx. $1,394).
- Ningbo Farmmi Baitong Trade Co., Ltd.: Sold for RMB 5,000 (approx. $697).
- Zhejiang Farmmi Biotechnology Co., Ltd.: Sold for RMB 10,000 (approx. $1,394).
Material Changes
The primary material changes involve the reduction of the company's subsidiary footprint through the following transactions:
- June 11, 2025: Zhejiang Yitang Medical Services Co., Ltd. agreed to sell 100% equity of two subsidiaries to Lishui Chida Logistics Co., Ltd.
- June 13, 2025: Zhejiang Farmmi Ecological Agricultural Technology Co., Ltd. agreed to sell 100% equity of Zhejiang Farmmi Biotechnology Co., Ltd. to Lishui Damushan Tea Co., Ltd.
- June 27, 2025: Zhejiang Famimi Biotechnology Co., Ltd. was dissolved via deregistration.
Management stated that none of the transferred or dissolved subsidiaries conducted substantial business prior to these actions.
Outlook, Risks, and Management Commentary
Management Commentary: The divestitures and deregistrations were explicitly intended to reduce costs associated with maintaining inactive corporate entities. Payment for the share transfers was required within 15 days of the agreement dates.
Risks and Contingencies: The filing notes that the descriptions of the share transfer agreements are not complete and are qualified by reference to the full text of the agreements attached as Exhibits 10.1 and 10.2.
Investor Verification Checklist
- Verify the receipt of purchase payments (RMB 25,000 total) within the stipulated 15-day window following the June 2025 agreements.
- Confirm the final deregistration status of Zhejiang Famimi Biotechnology Co., Ltd. with relevant Chinese governmental authorities.
- Review the full text of Exhibits 10.1 and 10.2 for any undisclosed liabilities or conditions attached to the share transfers.
- Assess the impact of these cost-reduction measures on the company's future operational structure and overhead expenses.